Fig. 7: RIG preclinical drug screen.

a In silico-predicted response of RIG vs. de novo GBM tumors to drug classes based on GSEA (NES, FDR, and number of genes in the geneset). b In vitro drug-screening results by drug class combined for RIG cell lines MAF-145 (gene expression Group B) and MAF-496 (gene expression Group A) showing percentage reduction in survival by drug class relative to the vehicle; the screen was performed using FDA-approved anticancer agents at a concentration of 1 μM for 120 h. c In vitro drug screen results in RIG cell lines using a 1 μM concentration; Group A (MAF-496) cell line response (surviving fraction vs. vehicle) is plotted on the x axis and Group B cell line (MAF-145) on the y axis. Dot colors correspond to drug class as shown in the legend. d In vitro validation results in RIG cell lines MAF-145 and MAF-496 for candidate drugs identified through the in vitro drug screen, IC₅₀ in nM. GSEA geneset enrichment analysis, NES normalized enrichment score, RIG radiation-induced high-grade glioma, GBM glioblastoma, FDR false discovery rate, FDA Food and Drug Administration.